We are committed to finding a cure for WM.
News: Health Canada has approved the use of Ibutrinib/rituximab combination
In a press release issued March 8th it was announced that Health Canada has approved the use of Ibutrinib in combination with rituximab for both first and later lines of treatment for patients of Waldenstroms Macroglobulinemia.
The release has been… Continue reading
FDA Approves First Chemotherapy-Free Treatment for Waldenström’s Macroglobulinemia
This morning, August 27, 2018, the US Food and Drug Administration (FDA) approved ibrutinib (IMBRUVICA, AbbVie) in combination with rituximab (RITUXAN) for the treatment of Waldenström’s macroglobulinemia. This combination is the first and only chemotherapy-free treatment option for patients with… Continue reading
Video: Dr. Dimopoulos Reflects on Ibrutinib Plus Rituximab in Waldenstrom Macroglobulinemia
Meletios Dimopoulos, MD, professor and chairman, Department of Clinical Therapeutics at the University of Athens School of Medicine, Athens, Greece, discusses the impact of the results from the iNNOVATE study of ibrutinib (Imbruvica) plus rituximab (Rituxan) in patients… Continue reading
Article: Primary Endpoints Met in Phase 3 of Imbruvica with Rituximab in Waldenstom’s Macroglobulinemia
DECEMBER 05, 2017
Mathew Shanley
A Phase 3 of Imbruvica (ibrutinib) in combination with Rituxan (rituximab) in relapsed/refractory and treatment-naïve patients with Waldenstrom’s macroglobulinemia (WM)… Continue reading
